Mar 06, 2020
BioLineRx to Report Annual 2019 Results on March 12, 2020
Jan 08, 2020
BioLineRx to Present at the 2020 Biotech Showcase
Nov 06, 2019
BioLineRx to Report Third Quarter 2019 Results on November 11, 2019
Oct 29, 2019
BioLineRx to Deliver Oral Presentation at ESMO Immuno-Oncology Congress 2019
Jul 30, 2019
BioLineRx to Report Second Quarter 2019 Results on August 6, 2019
Jun 28, 2019
BioLineRx Announces Change in Ratio of American Depositary Shares to Ordinary Shares
Jun 13, 2019
BioLineRx to Present at the JMP Securities 2019 Life Sciences Conference
May 13, 2019
Frost & Sullivan Publishes Annual Update on BioLineRx
May 07, 2019
BioLineRx to Report First Quarter 2019 Results on May 14, 2019
Mar 21, 2019
BioLineRx to Report Annual 2018 Results on March 28, 2019
Mar 14, 2019
BioLineRx to Present at the 29th Annual Oppenheimer Healthcare Conference
Feb 12, 2019
Frost & Sullivan Publishes Immediate Report on BiolineRx
Jan 02, 2019
BioLineRx to Present at the 2019 Biotech Showcase
Nov 01, 2018
BioLineRx to Report Third Quarter 2018 Results on November 8, 2018
Oct 03, 2018
BioLineRx Increases Stake in BL-8040, its Lead Oncology Platform in Late Stage Development for Multiple Oncology Indications
Aug 30, 2018
BioLineRx to Present at 20th Annual Rodman & Renshaw Global Investment Conference in New York
Aug 06, 2018
BioLineRx to Report Second Quarter 2018 Results on August 13, 2018
Jun 13, 2018
BioLineRx to Participate at JMP Securities 2018 Life Sciences Conference
May 16, 2018
BioLineRx to Report First Quarter 2018 Results on May 22, 2018
Mar 26, 2018
Frost & Sullivan Publishes Update Coverage Report on BiolineRx Ltd.: Continued advancement and execution of BiolineRx's lead oncology project - BL-8040; sufficient funds to support clinical strategy; stock target price remains at NIS 5.15